Momenta Phamaceuticals, Inc. (MNTA) Misses Q3 EPS by 12c
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Join SI Premium – FREE
Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q3 EPS of $1.18, $0.12 worse than the analyst estimate of $1.30. Revenue for the quarter came in at $87.9 million versus the consensus estimate of $90.92 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
- Star Equity Holdings (STRR) Misses Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
